Industry News

Join WhatsApp Channel

24 July 2025

NATCO Pharma’s Mekaguda API unit receives EIR from U.S. FDA following June inspection

NATCO Pharmas Active Pharmaceutical Ingredient (API) facility located in Mekaguda, near Hyderabad, has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration
24 July 2025

Zydus receives tentative USFDA approval for Ibrutinib tablets in multiple strengths

Zydus Lifesciences Limited has received tentative approval from the U.S. Food and Drug Administration (USFDA) to market Ibrutinib tablets in three strengths — 140 mg, 280 mg, and 420 mg. The approved products are generic versions of Imbruvica®, a widely used cancer medication in the United States.
22 July 2025

Pharmaceutical Cold Chain Packaging market set to surpass USD 11.6 Billion by 2034 amid biologics boom

According to a recent industry report, the market is poised to reach USD 11.6 billion by 2034, nearly doubling its 2024–2025 valuation of around USD 6 billion, with a projected compound annual growth rate (CAGR) of approximately 6.8%.
22 July 2025

ADIA to Invest USD 200 Million in Meril

A wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) has entered into definitive agreements to invest USD 200 million for an approximately 3% stake in Micro Life Sciences Private Limited (Meril), one of India’s leading medical devices companies.
This investment values Meril at an enterprise value of USD 6.6 billion. The transaction is subject to regulatory approval by the Competition Commission of India (CCI).
19 July 2025

Johnson & Johnson receives USFDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer

Johnson & Johnson that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200
18 July 2025

Knight Therapeutics announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

Knight Therapeutics Inc. specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for CREXONT® has been accepted for review by Health Canada.
17 July 2025

Corona Remedies acquires 7 Bayer brands, ahead of IPO

In a strategic move signaling its growing ambitions, Corona Remedies has acquired seven well-established pharmaceutical brands from Bayer’s Indian portfolio. The acquisition, effective July 16, 2025, includes one cardiology product and six widely used brands in the women’s health and fertility space.
17 July 2025

Nicox and Kowa inks up for USD 210.65 million for Glaucoma Treatment NCX 470 in U.S.

Nicox SA, an international ophthalmology company, today announced the signing of a major new agreement concerning NCX 470 with Kowa Company, Ltd., a Japanese company with a global pharmaceutical business engaged in ground-breaking research, development and marketing.
16 July 2025

Sun Pharma launches LEQSELVI™ in the U.S. after patent settlement with Incyte

Sun Pharmaceutical Industries Limited announced the official launch of LEQSELVI (deuruxolitinib tablets 8 mg) in the United States for the treatment of adults with severe alopecia areata
12 July 2025

Wockhardt to exit U.S. operations to prioritize innovation

Indian pharmaceutical company Wockhardt has announced a significant strategic shift in its U.S. operations, marking a new chapter focused on innovation-led growth and portfolio rationalization. The company is phasing out its conventional U.S. generics business to channel efforts into high-value specialty products and innovative therapies.